Olaratumab fails to show benefit in platinum-resistant ovarian cancer

  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Adding olaratumab to liposomal doxorubicin does not result in significant improvements in progression-free survival (PFS) or overall survival (OS) in platinum-resistant or platinum-refractory ovarian cancer, results from a phase II study suggest.

The open label study randomised patients with platinum-refractory or platinum-resistant advanced ovarian cancer 1:1 to receive liposomal doxorubicin (40 mg/m2 IV) every four weeks with or without olaratumab (20 mg/kg IV) every two weeks. A total of 123 patients were treated (62 olaratumab+liposomal doxorubicin; 61 liposomal doxorubicin).

Median PFS was 4.2 months for olaratumab+liposomal doxorubicin and 4.0 months for liposomal doxorubicin (stratified HR 1.043; 95% CI 0.698-1.558; P=.837). Median OS was 16.6 months and 16.2 months, respectively (HR 1.098; 95% CI 0.71-1.71).

In the platinum-refractory subgroup, median PFS was 5.5 months (95% CI 1.6-9.2) and 3.7 months (95% CI 1.9-9.2) with olaratumab+liposomal doxorubicin (n=15) and liposomal doxorubicin (n=16), respectively (HR 0.85; 95% CI 0.38-1.91).

Overall, 59.7 per cent of olaratumab+liposomal doxorubicin patients and 65.6 per cent of liposomal doxorubicin patients reported grade ≥3 adverse events. The most common treatment-emergent adverse events (all grades) were fatigue-related (61%), nausea (57%) and constipation (52%) with olaratumab+liposomal doxorubicin, and nausea (64%), fatigue-related (62%) and mucositis (46%) with doxorubicin alone.

The findings are published in BMC Cancer.